Effect of CTLA-4-Fc treatment of PBMCs on T-cell activation by influenza A virus and PHA
Treatment/activation . | CD4+CD38+, % . | CD4+CD69+, % . | CD8+CD38+, % . | CD8+CD69+, % . | IL-2, pg/mL . |
|---|---|---|---|---|---|
| None/none | 16.9 ± 6.8 | 2.5 ± 1.9* | 6.7 ± 0.8 | 1.9 ± 1.1* | 6.5 ± 2.4* |
| None/Flu | 18.7 ± 7.9 | 12.5 ± 0.4* | 7.3 ± 2.0 | 5.4 ± 0.6* | 22.3 ± 6.5* |
| CTLA-4/Flu | 23.0 ± 9.7 | 5 ± 1.5* | 8 ± 2.6 | 5.2 ± 0.3 | 5.1 ± 2.5* |
| None/PHA | 21.3 ± 9.3 | 23.5 ± 1.6* | 14.5 ± 0.5 | 15.8 ± 3.5* | 958 ± 91* |
| CTLA-4/PHA | 27.5 ± 5.7 | 11.3 ± 2.4* | 14.7 ± 1.5 | 14.0 ± 4.1 | 135 ± 41* |
| CTLA-4 + 1-MT/PHA | 25.3 ± 4.2 | 21.3 ± 2.6* | 13.8 ± 3.0 | 15.2 ± 3.9 | 580 ± 193* |
Treatment/activation . | CD4+CD38+, % . | CD4+CD69+, % . | CD8+CD38+, % . | CD8+CD69+, % . | IL-2, pg/mL . |
|---|---|---|---|---|---|
| None/none | 16.9 ± 6.8 | 2.5 ± 1.9* | 6.7 ± 0.8 | 1.9 ± 1.1* | 6.5 ± 2.4* |
| None/Flu | 18.7 ± 7.9 | 12.5 ± 0.4* | 7.3 ± 2.0 | 5.4 ± 0.6* | 22.3 ± 6.5* |
| CTLA-4/Flu | 23.0 ± 9.7 | 5 ± 1.5* | 8 ± 2.6 | 5.2 ± 0.3 | 5.1 ± 2.5* |
| None/PHA | 21.3 ± 9.3 | 23.5 ± 1.6* | 14.5 ± 0.5 | 15.8 ± 3.5* | 958 ± 91* |
| CTLA-4/PHA | 27.5 ± 5.7 | 11.3 ± 2.4* | 14.7 ± 1.5 | 14.0 ± 4.1 | 135 ± 41* |
| CTLA-4 + 1-MT/PHA | 25.3 ± 4.2 | 21.3 ± 2.6* | 13.8 ± 3.0 | 15.2 ± 3.9 | 580 ± 193* |
Mean values ± SEM are shown.
Statistically significant difference (P < .05).